A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations - CNRS - Centre national de la recherche scientifique
Article Dans Une Revue Science Translational Medicine Année : 2020

A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations

1 CNRS-UMR3569 - Virus et Immunité - Virus and immunity
2 VRI - Vaccine Research Institute [Créteil, France]
3 UPCité - Université Paris Cité
4 Découverte de pathogènes – Pathogen discovery
5 Immunologie humorale - Humoral Immunology
6 GMV-ARN (UMR_3569 / U-Pasteur_2) - Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses
7 Epidémiologie des Maladies Emergentes - Emerging Diseases Epidemiology
8 Département de Virologie - Department of Virology
9 CNR - laboratoire coordonnateur - Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris]
10 Biologie des ARN et virus influenza - RNA Biology of Influenza Virus
11 Laboratoire commun Pasteur-TheraVectys
12 Virologie Moléculaire et Vaccinologie / Molecular Virology and Vaccinology
13 Laboratoire d’innovation : vaccins – Innovation lab : vaccines
14 PPR - Plateforme technologique Production et purification de protéines recombinantes – Production and Purification of Recombinant Proteins Technological Platform
15 Virologie Structurale - Structural Virology
16 IAME (UMR_S_1137 / U1137) - Infection, Anti-microbiens, Modélisation, Evolution
17 AP-HP - Hôpital Bichat - Claude Bernard [Paris]
18 ICAReB - Investigation Clinique et d’Accès aux Ressources Biologiques (Plate-forme) - Clinical Investigation and Access to BioResources
19 Coordination du Risque Epidémique et Biologique [CHU Necker]
20 EFS - Etablissement Français du Sang
21 CHU - BREST - Hôpital de la Cavale Blanche - CHRU Brest
22 CIC 1417 - CIC Cochin Pasteur
23 Santé publique France - French National Public Health Agency [Saint-Maurice, France]
24 CESPA - Centre d'épidémiologie et de santé publique des armées [Marseille]
25 DGS - Direction Générale de la Santé
26 CNAM - Conservatoire National des Arts et Métiers [CNAM]
27 PACRI - Pasteur-Cnam Risques infectieux et émergents
28 Direction de la recherche médicale de l'Institut Pasteur
29 ENVA - École nationale vétérinaire d'Alfort
François Anna
Pascal Morel
Felix Rey
  • Fonction : Auteur
  • PersonId : 1058991
Hugo Mouquet

Résumé

It is of paramount importance to evaluate the prevalence of both asymptomatic and symptomatic cases of SARS-CoV-2 infection and their differing antibody response profiles. Here, we performed a pilot study of four serological assays to assess the amounts of anti-SARS-CoV-2 antibodies in serum samples obtained from 491 healthy individuals before the SARS-CoV-2 pandemic, 51 individuals hospitalized with COVID-19, 209 suspected cases of COVID-19 with mild symptoms, and 200 healthy blood donors. We used two ELISA assays that recognized the full-length nucleoprotein (N) or trimeric spike (S) protein ectodomain of SARS-CoV-2. In addition, we developed the S-Flow assay that recognized the S protein expressed at the cell surface using flow cytometry, and the luciferase immunoprecipitation system (LIPS) assay that recognized diverse SARS-CoV-2 antigens including the S1 domain and the carboxyl-terminal domain of N by immunoprecipitation. We obtained similar results with the four serological assays. Differences in sensitivity were attributed to the technique and the antigen used. High anti-SARS-CoV-2 antibody titers were associated with neutralization activity, which was assessed using infectious SARS-CoV-2 or lentiviral-S pseudotype virus. In hospitalized patients with COVID-19, seroconversion and virus neutralization occurred between 5 and 14 days after symptom onset, confirming previous studies. Seropositivity was detected in 32% of mildly symptomatic individuals within 15 days of symptom onset and in 3% of healthy blood donors. The four antibody assays that we used enabled a broad evaluation of SARS-CoV-2 seroprevalence and antibody profiling in different subpopulations within one region.
Fichier principal
Vignette du fichier
eabc3103.full.pdf (2.53 Mo) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

pasteur-03139185 , version 1 (11-02-2021)

Licence

Identifiants

Citer

Ludivine Grzelak, Sarah Temmam, Cyril Planchais, Caroline Demeret, Laura Tondeur, et al.. A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations. Science Translational Medicine, 2020, 12 (559), pp.eabc3103. ⟨10.1126/scitranslmed.abc3103⟩. ⟨pasteur-03139185⟩
235 Consultations
407 Téléchargements

Altmetric

Partager

More